📰 ET Markets ⚪ NEUTRAL 🕒 09 Oct 2026, 09:45 AM IST

Fusion CX sets price band for Rs 702 crore IPO; issue opens on October 14

⚡ Instant Key Takeaways (TL;DR)

🎯

Core Development: Fusion CX sets price band for Rs 702 crore IPO; issue opens on October 14

📊

Market & Financial Impact: Fusion CX has set a price band of Rs 275–289 per share for its Rs 702 crore IPO, which will open on October 14 and close on October 16. The issue comprises a fresh issue worth Rs 500 crore and an offer for sale (OFS) of Rs 202 crore. Allotment is expected on October 19, with shares scheduled to list on the BSE and NSE on October 22, 2026.

💡

Actionable Insight: Monitor price volume action at market open; check key technical support/resistance levels.

Fusion CX has set a price band of Rs 275–289 per share for its Rs 702 crore IPO.

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

What is the real impact of 13x jump in cash transfers to women?

The NBFC saga - Part 2: Line drawn in 2006 is reason for the headlines today

📰

Official Publisher Attribution: This report is aggregated from Economic Times. ZeroLive provides live aggregation, automated sentiment synthesis, and exchange disclosure monitoring for retail market participants.

Read Original Full Coverage on Economic Times ↗

Fusion CX sets price band for Rs 702 crore IPO; issue opens on October 14

🔥 More Live Market Stories

[UDAYJEW] Certificate under SEBI (Depositories and Participants) Regulations, 2018 - Uday Jewellery Industries Limited

Up 15,400% in 5 years, multibagger stock Cupid hits record high - What's fuelling the rally? Check outlook, stop loss

[PIXTRANS] Certificate under SEBI (Depositories and Participants) Regulations, 2018 - Pix Transmissions Limited

Paramount Syntex shares hit lower circuit after debuting at 10% discount on BSE SME

Max Healthcare, Apollo, other hospital shares rise up to 4%: Here's why

Lupin, Sun Pharma, Zydus Lifesciences gain up to 1.5% as Nomura retains 'Buy' ratings amid pharma growth surge